Caranx medical develops the AIIR platform to broaden the adoption of endoluminal techniques worldwide
Increasing demand worldwide drives the market
Today, endoluminal treatments exist to treat certain diseases, like TAVI for the structural heart or the Endo gastric sleeve for bariatrics. However, these techniques remain complex and require a significative learning curve, limiting their adoption at a large scale. In parallel, treatment needs of the world’s population continue to grow significantly.
by 2045
Population growth is driving increasing demand globally, both in developed and emerging countries
50%
of the growth by 2045
AGING POPULATION
Aging of population increases dramatically number of patients suffering from cardiovascular or metabolic diseases worldwide
people in middle class by 2030
GROWING ACCESS TO HEALTHCARE
The emergence of a middleclass with increased financial means impacts the demand for access to advanced care in many regions
Shortage of specialized clinicians put pressure on healthcare systems
Even in the most developed countries, there is already a shortage of specialized clinicians, such as neuro-radio interventionalists or interventional cardiologists. This pressure on healthcare systems will continue to increase in the coming years, affecting patients’ access to care.
54 000 - 139 000
clinicians by 2033
IN THE US
230 000
clinicians
IN THE EUROPE
4 000
cardiologists by 2025 in the US
CARDIOLOGY
Across the globe, 6.4M physicians are needed
With AiiR platfrom, we aim at initiating this shift, by simplifying complex procedures and giving greater access to minimally-invasive care to patients worldwide.
AI trained on our own multi-modal database relying on several thousands of patients, allowing to build a digital twin able to anticipate potential complications and to make specific recommendations for a specific patient.
Real-time multi-modal medical image analysis allow fast and intelligent decision-making.
Autonomous motions supervised by the clinician allowing higher precision. The clinician can also teleoperate the robot with AI guidance at any stage.
TAVIPILOT is the first application of the Caranx medical AiiR platform that will enable a more precise aortic valve positioning, leading to reaching the level of experts.
Events
Nice, France, April 16 th 2024 – Caranx Medical, announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal.
The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team.
“This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients’ lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx.
“This major medical first lies not only in the technical achievement of Caranx Medical’s engineers, but also in the impact that this technology will have on interventional cardiology practice. By simplifying and standardizing a complex procedure, the robot we have developed opens up new
possibilities for improving the performance and safety of TAVI procedures” says Dr. Eric Sejor, co-founder and CMO of Caranx.